Keyphrases
Dabigatran
100%
Successful Treatment
100%
Nephropathy
100%
Idarucizumab
100%
Acute Kidney Injury
50%
Anticoagulants
33%
Renal Function
33%
Kidney Injury
33%
Hospitalization
16%
Working Diagnosis
16%
Safety Profile
16%
Warfarin
16%
Apixaban
16%
Direct Oral Anticoagulants
16%
Rivaroxaban
16%
Management Strategy
16%
Complete Recovery
16%
Older Patients
16%
Harmful Effects
16%
Dialysis
16%
Hematuria
16%
Aged 80 Years and over
16%
New-onset Atrial Fibrillation
16%
Renal Injury
16%
Urine Specimen
16%
Direct Inhibitors
16%
Factor Xa
16%
Edoxaban
16%
Thrombin Inhibitor
16%
Praxbind
16%
Medicine and Dentistry
Nephropathy
100%
Dabigatran
100%
Idarucizumab
100%
Acute Kidney Injury
50%
Kidney Injury
50%
Kidney Function
33%
Antithrombotic
33%
Erythrocyte
16%
Warfarin
16%
Hematuria
16%
New-Onset Atrial Fibrillation
16%
Prothrombinase
16%
Direct Oral Anticoagulant
16%
Edoxaban
16%
Apixaban
16%
Rivaroxaban
16%
Direct Thrombin Inhibitor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Dabigatran
100%
Kidney Disease
100%
Idarucizumab
100%
Acute Kidney Failure
50%
Kidney Injury
50%
Anticoagulant Agent
33%
Rivaroxaban
16%
Direct Oral Anticoagulant
16%
Apixaban
16%
Warfarin
16%
Hematuria
16%
Thrombin Inhibitor
16%
New-Onset Atrial Fibrillation
16%
Blood Clotting Factor 10a
16%
Edoxaban
16%